PODCAST | Finance

Financing thaw? Plus: protein design & China audits

A flurry of follow-ons led by Karuna suggests a more receptive market for companies with recent catalysts

August 16, 2022 12:28 AM UTC

A flurry of follow-on financings last week suggests a receptive market for companies with recent catalysts, BioCentury’s Paul Bonanos says on the latest BioCentury This Week podcast. Bonanos and colleagues discuss what last week’s offerings, led by schizophrenia company Karuna Therapeutics Inc. (NASDAQ:KRTX), say about which companies might be able to tap the public markets and under what circumstances. The podcast team also examines how computational protein design is shifting its center of gravity from mechanistic calculations based on physical forces to more powerful machine learning approaches trained on reams of data, and why a deal between the SEC and its Chinese counterpart on cross-border audits could be nearly in hand.

BCIQ Company Profiles

Karuna Therapeutics Inc.